+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
ID07123545

Study of Personalized Neoantigen-Specific T-Cell Therapy for Advanced Liver Cancer in Adults Aged 18 to 75

Led by Zhejiang University · Updated on 2025-08-14

20

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating an autologous neoantigen-specific T-cell therapy called iNeo-Vac-T01 for patients with advanced hepatocellular carcinoma who have not responded to two or more prior systemic treatments. This open-label, single-arm phase III trial aims to assess the feasibility, safety, and anti-tumor effects of this personalized immunotherapy approach in this patient population. The study is sponsored by Zhejiang University and focuses on advanced cancer that is measurable by imaging and has progressed despite previous therapies. Participants receive a personalized neoantigen peptide vaccine iNeo-Vac-P01 given by subcutaneous injection on Days 1, 4, 8, 15, 22, 52, and 82, followed by booster shots every 2 to 3 months. Starting at Week 9, patients undergo intravenous infusion of the personalized T cell therapy iNeo-Vac-T01 using a dose escalation design. Before this infusion, a lymphodepleting regimen with cyclophosphamide and fludarabine is administered. After infusion, supportive therapy with interleukin-2 is given for 10 days to support immune response. During the study, participants will have regular visits for treatment administration and monitoring for up to three years. Researchers will evaluate the success of administering iNeo-Vac-T01 and monitor for adverse events. Secondary measures include progression-free survival, tumor response rates, and immune response in the blood. Patients will undergo laboratory tests, imaging scans, and genomic profiling of tumor tissue to support treatment planning and safety assessments. The total participation duration may last several years as patients are followed for clinical outcomes and safety.

CONDITIONS

Brief Title

Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma

Research Team

T

Tingbo Liang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here